These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38680970)

  • 1. Pathways for Diagnosing and Treating CKD-Associated Pruritus: A Narrative Review.
    Rigatto C; Collister D; Granger-Vallée A; Girard L; Hingwala J; Karaboyas A; Levin A; McFarlane P; Pisoni R; Prasad B; Proulx N; Schwartz D; Sood M; Suri R; Tennankore K
    Can J Kidney Health Dis; 2024; 11():20543581241238808. PubMed ID: 38680970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.
    Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J
    Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Have We Just Scratched the Surface? A Narrative Review of Uremic Pruritus in 2020.
    Martin CE; Clotet-Freixas S; Farragher JF; Hundemer GL
    Can J Kidney Health Dis; 2020; 7():2054358120954024. PubMed ID: 33117546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.
    Fugal J; Serpa SM
    Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do you feel itchy? A guide towards diagnosis and measurement of chronic kidney disease-associated pruritus in dialysis patients.
    Manenti L; Leuci E
    Clin Kidney J; 2021 Dec; 14(Suppl 3):i8-i15. PubMed ID: 34987778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study.
    Weiner DE; Vervloet MG; Walpen S; Schaufler T; Munera C; Menzaghi F; Wen W; Bhaduri S; Germain MJ;
    Kidney Med; 2022 Oct; 4(10):100542. PubMed ID: 36185706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, patient burden and physicians' perception of pruritus in haemodialysis patients.
    Engler F; Kerschbaum J; Keller F; Mayer G;
    Nephrol Dial Transplant; 2024 Jan; 39(2):277-285. PubMed ID: 37429597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Burden of Pruritus Associated With CKD: A Mixed Methods Analysis Among Patients Undergoing Dialysis.
    Menzaghi F; Vernon MK; Mattera M; Cirulli J; Wen W; Spencer RH; Munera C
    Kidney Med; 2023 Sep; 5(9):100696. PubMed ID: 37637864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.
    Rastogi A; Fishbane S; Lerma E
    Expert Rev Clin Pharmacol; 2023 May; 16(5):387-400. PubMed ID: 37010031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
    Topf J; Wooldridge T; McCafferty K; Schömig M; Csiky B; Zwiech R; Wen W; Bhaduri S; Munera C; Lin R; Jebara A; Cirulli J; Menzaghi F
    Kidney Med; 2022 Aug; 4(8):100512. PubMed ID: 36016762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review.
    Wala K; Szepietowski JC
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for itch in people with advanced chronic kidney disease.
    Hercz D; Jiang SH; Webster AC
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011393. PubMed ID: 33283264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological interventions for pruritus in adult palliative care patients.
    Boehlke C; Joos L; Coune B; Becker C; Meerpohl JJ; Buroh S; Hercz D; Schwarzer G; Becker G
    Cochrane Database Syst Rev; 2023 Apr; 4(2023):CD008320. PubMed ID: 37314034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.
    Lipman ZM; Yosipovitch G
    Expert Opin Pharmacother; 2021 Apr; 22(5):549-555. PubMed ID: 33190563
    [No Abstract]   [Full Text] [Related]  

  • 17. [Difelikefalin and treatment of severe pruritus associated with chronic kidney disease - Real-life retrospective study in a dialysis center].
    Brasme R; Cartery C; Goubet M; Hennino MF; Maisonneuve N
    Nephrol Ther; 2024 Jun; 20(3):1-9. PubMed ID: 38874419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difelikefalin for pruritus associated with renal disease.
    Manenti L; Fenaroli P
    Drugs Today (Barc); 2022 Sep; 58(9):427-435. PubMed ID: 36102903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
    Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
    J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.